Nearly 5 months after the FDA did not approve reproxalap for dry eye, Aldeyra Therapeutics has announced a plan to resubmit a new drug application for the reactive aldehyde species modulator, according to a press release.
The company plans to initiate a dry eye chamber clinical trial in the first half of 2024 and expects to resubmit the NDA in the second half of the year, contingent on positive results from the trial, according to the release.
“The planned dry eye chamber clinical trial, if successful, could represent the first (Read more...)